ABOUT DANAHER LIFE SCIENCES
Every day, scientists around the world are dedicated to unraveling the mysteries of disease, discovering novel therapies and vaccines, and conducting crucial drug testing. At Danaher Life Sciences, a collection of businesses within Danaher Corporation, we play a pivotal role in facilitating these cutting-edge scientific endeavors. Our comprehensive capabilities go beyond research, enabling us to drive the development of innovative biopharmaceuticals, revolutionary cell and gene therapies, and other breakthrough treatments that propel patient health forward and enhance treatment outcomes.


FEATURED ARTICLES
-
Cancer mortality is declining, but the need for earlier action remains. Gain insight into how MCED and MRD are advancing cancer detection and surveillance, helping clinicians identify disease sooner.
-
New advances in MCED and MRD monitoring are transforming cancer care. Fueled by NGS insights, see how these approaches are shifting treatment decisions toward more proactive strategies.
-
Whole exome sequencing is accelerating genetic discovery. Learn how it enables biomarker detection, supports cancer research, and expands opportunities for scalable, future-ready genomic analysis.
-
Build stronger qPCR assays by delving into how to troubleshoot common issues, improve reproducibility, and confidently quantify gene expression across a wide range of experimental conditions.
-
Skip time-consuming extraction steps and achieve reliable qPCR results. Direct amplification methods help researchers detect respiratory pathogens more efficiently across saliva and nasal samples.
-
Skip extraction and move straight to amplification with a streamlined qPCR workflow. Achieve comparable performance across multiple targets while reducing costs and saving time.
-
Residual inhibitors in GI-derived DNA can hinder qPCR performance. An optimized approach improves inhibitor tolerance and enables earlier target detection, delivering more reliable amplification.
-
Accurately identifying genetic duplications in leukemia requires more than conventional sequencing. See how advanced enrichment and analysis approaches enable deeper insight into variant structure.
-
Learn how sequencing strategy, library prep, and data quality considerations shape outcomes in modern genomics. Clear insights help optimize workflows across a wide range of sequencing applications.
-
Bringing CRISPR therapies to market requires navigating complex global regulations. Learn how strategic planning, risk assessment, and manufacturing alignment can streamline development.
-
Sequencing performance can drop quickly with low-quality, low-input FFPE DNA. Gain insight into how one approach helps labs minimize repeats and maintain more consistent results.
-
Extraction-free qPCR enables faster, lower-cost detection of UTI-associated bacteria directly from urine samples. Explore how this approach simplifies workflows and accelerates time to results.
-
Skip extraction and still achieve reliable qPCR results. See how direct amplification of plant samples enables faster workflows, lower costs, and clear detection of resistance markers.
-
Simultaneous analysis of HRD, TMB, and MSI offers a more complete view of tumor biology. A modular sequencing approach enables efficient workflows, conserves samples, and delivers deeper insights.
-
Early TOC excursions often reveal hidden risks in water systems. Capturing samples at the moment of deviation helps teams confirm root causes faster, reduce uncertainty, and maintain control.
-
Accurate TOC results shouldn’t depend on sample order. See how low-level measurements remain reliable even after high-TOC analysis, helping reduce false positives and streamline decisions.
-
AI agents are reshaping biopharma research, offering new ways to analyze data. Find out how success depends on strong data foundations, governance, and thoughtful adoption strategies.
-
Global research teams were generating critical data in disconnected systems, hindering collaboration. Explore how unified workflows and a shared data backbone strengthen efficiency.
-
Biopharma–CRO partnerships often struggle with fragmented communication. Gain insight into how streamlined, automated workflows improve transparency, data quality, and operational speed.
-
Precision medicine is opening new possibilities for IMIDs by moving beyond symptom‑based care. Find out how emerging multi‑omics tools are reshaping how these complex diseases are understood.
CONTACT INFORMATION
Danaher Life Sciences
500 Old Connecticut Path
Framingham, MA 01701
UNITED STATES